Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

• Status: Completed
• Trial end date: 2020-02-25
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to assess the efficacy of Iv hyoscine butylbromide in preventing Bradycardia during cesarean section under spinal anaesthesia with local anaesthetic and morphine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Butylscopolammonium Bromide; Scopolamine

Criteria

Inclusion Criteria:

• ASA physical status class I-II.

• Age: 18 Years to 40 Years.

• Women scheduled for elective Cesarean section under spinal anesthesia.

• indications for CS other than fetal or maternal pathology.

Exclusion Criteria:

• Height < 150 or > 180 cm

• Body mass index (BMI) >35 kg/m2

• Contraindication for central neuraxial block

• Refusal to undergo regional anesthesia

• Known allergy to any of the study drugs,

• Infection at the site of injection,

• Coagulopathy,

• Indication to general anesthesia

• Baseline bradycardia (heart rate < 60/min), or any cardiovascular disease

• Patients taking β-adrenergic blockers or any drugs that may alter normal response to study drugs.

• Arrhythmia such as atrial fibrillation, supraventricular tachycardia, heart block greater than first degree, left bundle branch block,

• Hypertension (systolic blood pressure more than 140 mm Hg or diastolic blood pressure more than 90 mm Hg), unstable angina or cardiomyopathy,

• Associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic impairment or renal impairment)